Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer
| Autor: | Pierre Ferre, Jean-Marc Tourani, Gilles Robinet, Marie-Claire Pinel, Caroline Tournoux-Facon |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Cancer Research Lung Neoplasms Maximum Tolerated Dose medicine.drug_class Adenocarcinoma Vinblastine Vinca alkaloid Carboplatin chemistry.chemical_compound Pharmacokinetics Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Tissue Distribution Lung cancer neoplasms Aged Neoplasm Staging Antitumor activity Vinflunine business.industry Middle Aged medicine.disease Prognosis respiratory tract diseases Survival Rate Oncology chemistry Cancer research Carcinoma Squamous Cell Female Non small cell business Follow-Up Studies |
| Zdroj: | American journal of clinical oncology. 35(4) |
| ISSN: | 1537-453X |
| Popis: | Vinflunine (VFL) (Javlor(®)), a novel fluorinated semisynthetic vinca alkaloid has shown significant antitumor activity in advanced non-small cell lung cancer (NSCLC). We propose to define the recommended dose (RD) of VFL in combination with carboplatin in advanced NSCLC patients.This phase I and pharmacokinetic study was designed to determine the maximum tolerated dose and to establish the RD of VFL in combination with carboplatin. Twenty-one chemonaive patients with advanced NSCLC were treated with a first-line chemotherapy of VFL and carboplatin both given on day 1 every 3 weeks with 3 dose levels.Five patients experienced a dose limiting toxicity consisting of constipation in 2 patients and febrile neutropenia in 2 patients. One patient experienced grade 3 abdominal pain concurrent with grade 4 neutropenia. The combination of VFL (320 mg/m(2)) and carboplatin AUC6 was defined as the maximum tolerated dose. The RD was established at the dose of VFL (320 mg/m(2)) combined with carboplatin AUC5. At the RD, 12 patients received a median number of 3 cycles of the combination. Neither VFL nor carboplatin seemed to be influencing the pharmacokinetics of the other. Among 19 patients evaluable for tumor response, 7 had a partial response and 7 experienced stable disease.The combination of VFL (320 mg/m(2)) and carboplatin AUC 5 given once every 3 weeks is established as the RD of the combination, which was shown to be active in these chemonaive NSCLC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|